JP2023544141A - ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した神経系疾患を処置する方法 - Google Patents

ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した神経系疾患を処置する方法 Download PDF

Info

Publication number
JP2023544141A
JP2023544141A JP2023519464A JP2023519464A JP2023544141A JP 2023544141 A JP2023544141 A JP 2023544141A JP 2023519464 A JP2023519464 A JP 2023519464A JP 2023519464 A JP2023519464 A JP 2023519464A JP 2023544141 A JP2023544141 A JP 2023544141A
Authority
JP
Japan
Prior art keywords
aimp2
promoter
subject
mir
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544141A5 (enExample
Inventor
ジン ウ チェ，
キュンファ ベク，
Original Assignee
ジェネロス カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネロス カンパニー， リミテッド filed Critical ジェネロス カンパニー， リミテッド
Publication of JP2023544141A publication Critical patent/JP2023544141A/ja
Publication of JP2023544141A5 publication Critical patent/JP2023544141A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023519464A 2020-09-30 2021-09-30 ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した神経系疾患を処置する方法 Pending JP2023544141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085950P 2020-09-30 2020-09-30
US63/085,950 2020-09-30
PCT/IB2021/059017 WO2022070141A1 (en) 2020-09-30 2021-09-30 METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF

Publications (2)

Publication Number Publication Date
JP2023544141A true JP2023544141A (ja) 2023-10-20
JP2023544141A5 JP2023544141A5 (enExample) 2025-03-06

Family

ID=80949780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519464A Pending JP2023544141A (ja) 2020-09-30 2021-09-30 ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した神経系疾患を処置する方法

Country Status (9)

Country Link
US (1) US20230374092A1 (enExample)
EP (1) EP4221759A4 (enExample)
JP (1) JP2023544141A (enExample)
KR (1) KR20230079267A (enExample)
CN (1) CN116507370A (enExample)
AU (1) AU2021354996A1 (enExample)
CA (1) CA3192710A1 (enExample)
MA (1) MA71714A (enExample)
WO (1) WO2022070141A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터
EP4221760A4 (en) * 2020-09-30 2025-08-13 Generoath Co Ltd METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR MIR-142 AND RELATED COMPOSITIONS
CN119343154A (zh) * 2022-05-13 2025-01-21 杰内罗蒂股份有限公司 使用AIMP2-DX2和任选的miR-142靶序列及其组合物治疗视网膜退行性疾病的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190298858A1 (en) * 2018-03-29 2019-10-03 Generoath Co., Ltd Pharmaceutical composition comprising aimp2-dx2 for preventing or treating neuronal diseases and use thereof
WO2020188472A1 (en) * 2019-03-15 2020-09-24 Generoath Co., Ltd. Vectors containing aimp2-dx2 and target nucleic acids for mir-142 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
KR101749138B1 (ko) * 2015-10-07 2017-06-20 원광대학교산학협력단 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
KR102349061B1 (ko) * 2019-03-15 2022-01-10 주식회사 제너로스 생착능이 증가된 줄기세포의 제조 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190298858A1 (en) * 2018-03-29 2019-10-03 Generoath Co., Ltd Pharmaceutical composition comprising aimp2-dx2 for preventing or treating neuronal diseases and use thereof
WO2020188472A1 (en) * 2019-03-15 2020-09-24 Generoath Co., Ltd. Vectors containing aimp2-dx2 and target nucleic acids for mir-142 and uses thereof

Also Published As

Publication number Publication date
WO2022070141A1 (en) 2022-04-07
EP4221759A4 (en) 2025-10-15
AU2021354996A1 (en) 2023-04-20
CN116507370A (zh) 2023-07-28
AU2021354996A9 (en) 2023-04-27
EP4221759A1 (en) 2023-08-09
CA3192710A1 (en) 2022-04-07
US20230374092A1 (en) 2023-11-23
MA71714A (fr) 2025-05-30
KR20230079267A (ko) 2023-06-05

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
KR20230079267A (ko) AIMP2-DX2 및 선택적으로 miR-142에 대한 표적 서열 및 이의 조성물을 이용한 신경질환의 치료방법
RU2723101C2 (ru) Вектор, способ лечения хороидермии, способ селективной экспрессии полинуклеотида
RU2757932C2 (ru) Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта
JP7291423B2 (ja) ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用
KR20230110503A (ko) AIMP2-DX2 및 선택적으로 miR-142에 대한 표적 서열 및 이의 조성물을 이용한 노인성 황반 질환의 치료방법
KR20210116559A (ko) 중추신경계 질환의 치료 방법
WO2022055320A1 (ko) 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터
US20250281573A1 (en) Methods of Treating Retinal Degenerative Diseases Using AIMP2-DX2 and Optionally a Target Sequence for miR-142 and Compositions Thereof
KR102626543B1 (ko) AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터
KR20260028192A (ko) 신경퇴행성 질환 및 장애의 치료 및 예방용 조성물 및 방법
EA048975B1 (ru) Векторы, содержащие aimp2-dx2 и целевые нуклеиновые кислоты для mir-142, и их применение
Wood Development of AAV-mediated gene therapy for autosomal recessive bestrophinopathy
HK1252168B (en) Genetic construct

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260116